Mission & Vision
Based On The World’s first DNA Aptamer Patent, Becoming A Global Therapeutics and Healthcare Market Leader
Based On The World’s first DNA Aptamer Patent, Becoming A Global Therapeutics and Healthcare Market Leader
Entering the global healthcare market with the start of commercializing the first DNA Aptamer in worldwide
Intellectual Property Status
Area | Applied | PCT | Registered | Total |
---|---|---|---|---|
Aptamin® | 24 | 2 | 7 | 33 |
Therapeutics | 12 | 12 | ||
Early Diagnosis | 5 | 5 | ||
Other | ||||
Total | 41 | 2 | 7 | 50 |
Jung-Wook Shim
Aptamin Lab Co, CEO
ADT CAPS Co, V. President
Naturerepublic Co, V. President
The Face Shop, executive director
Economics at Seoul National University
Kang-Joon Cho
Aptamin Lab Co, V. President
KTB Investment & Securities Co, director
LIG Investment & Securities Co, director
Economics at Seoul National University
Yoonsung Kim, M.D., Ph.D.
Rutgers University Medical School
Weill Cornell Medicine
Ph.D. in Medical School, Cornell Univ.
Jae-Seung Kang, Ph.D.
SNU therapeutics
Anatomy and Cell Biology
Ph.D. Seoul National University College of therapeutics
Yeongjeong Kim, Ph.D.
Dept. of Nursing Science,
Kyunghee University
Post-doc. Fellowship, Weill Medical School, Cornell Univ.
Ph.D, Kyunghee University
Jin-ho Lee
Pentaheal Clinic, director
Yonsei University College of therapeutics